2nd Annual Companion Diagnostics & Biomarkers 2019


The BioTech Pharma Summit is proud to present the 2nd Annual Companion Diagnostics & Biomarkers 2019. This innovative B2B event will enable the participants to learn about the latest trends, developments, business models and strategies in the companion diagnostics & Biomarkers.

Over 100+ delegates representing global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions will be joining the Companion Diagnostics & Biomarkers 2019

Companion diagnostics market is growing due to continuous advancement in medical technology both for the diagnosis and the treatment of patients. Rise in the prevalence of diseases like cancer & HIV is fueling to the growth of companion diagnostics as it assist in determining the patient specific dose and drugs.

Over 20+ presentations and case studies focused on the key issues in Companion Diagnostics & Biomarkers. Join us at the Companion Diagnostics & Biomarkers 2019 in Porto

The 2nd Annual Companion Diagnostics & Biomarkers 2019 will provide valued information about new IVD regulations, Dx reimbursement strategy, market access strategy to ensure successful commercialization with pharma & biotech companies. We will also provide solutions to assist in all stages of CDx development from the biomarker discovery process through CDx commercialization.

We sincerely hope you are able to join us for this year’s meeting and be part of a new paradigm of precision medicine at the 2nd Annual Companion Diagnostics & Biomarkers 2019!


  • Methods and Strategies to Profile the tumor Microenvironment
  • Clinical tumor sequencing: opportunities and challenges for precision cancer medicine.
  • Liquid biopsy- the future of cancer diagnosis and precision medicine.
  • Latest US and EU CDx regulation and guidance
  • Genetic biomarker-based patient stratification in non-oncology
  • The future & challenges of precision medicine
  • Innovative biomarker-driven clinical trials
  • Understanding payer perspectives and RWE approaches
  • Recent Developments in Companion Diagnostics in Auto-immune Disease and Immunooncology
  • Strategic Partnerships for CDx – Challenges and Opportunities
  • The Challenge of Personalised Healthcare in Respiratory Disease
  • Diagnostic Strategies for Cancer Immune Therapies
  • Developing and Implementing Effective Biomarker Strategies for Immuno-Oncology Trials
  • Exosome-derived epigenetic biomarkers for saliva diagnostics
  • A global perspective on BRCA gene testing
  • Image-based CDx solutions
  • Development and Commercialization of Biomarker Assays for Therapeutic and Diagnostic Guidance
  • Genomics challenges from a single sample to large clinical studies


The BioTech Pharma Summit (EPM Group) are exclusive events designed for senior level attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, CRO and solution provider companies, along with highly esteemed mem- bers of academic and government institutions.
Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders and Managers including:

  • Companion Diagnostics
  • Molecular Diagnostics
  • Personalized Healthcare
  • Clinical Development
  • Regulatory Affairs
  • Molecular Diagnostics
  • Biomarkers
  • Medical Sciences
  • Experimental Medicine
  • Translational Medicine
  • Immunology
  • Genomics
  • Insurers
  • Patient Advocates
  • Payers
  • Market Access
  • Medical Sciences
  • Commercialisation
  • Oncology
  • Non-oncology
  • Rare Diseases
  • Drug Development
  • Research
Senior Director, Genomics Platform Project & Alliance Management at Broad Institute
Scientific Regulatory Expert Biomedicines at Paul-Ehrlich-Institut (PEI)
Chief Commercial Officer at Genomics England
Professor of Translational Science at University College Dublin
Professor in Molecular Oncology at Barts Cancer Institute, Queen Mary University of London
Senior Scientist at Austrian Institute of Technology
Managing Director at Martina Kaufmann Strategic Consulting
Vice President Translational Medicine at Pierre Fabre
Professor Pharmacogenetics
Director, Biomarkers
Chair of the Department of Biostatistics
Vice President, R&D, Clinical Sequencing Division
Chief Business Officer
Chief Scientific Officer
Business Development Manager
Senior Biologist
Global head of healthcare partnerships
Head of Clinical Development at AIPES
Vice President of Market Access
Executive Director
 Vice President, Development and Operations
Senior Medical Oncologist & Professor of Medicine
Vice President MHS global IVD
Professor of Pharmacology and Personalised Medicine
Event Details